Trial Profile
The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary)
- Indications Cardiovascular disorders; Hyperuricaemia
- Focus Therapeutic Use
- 23 Jul 2019 Status changed from active, no longer recruiting to completed.
- 05 May 2016 Planned End Date changed from 1 Feb 2016 to 1 Jan 2017.
- 05 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Jan 2017.